SCHEMBL802067

SCHEMBL802067

Cc1cc(Nc2cc(-c3ccccc3C)nc(C3CCCCC3)c2)n[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 5/20 0.38
AURKB Q96GD4 4/20 0.38
GSK3B P49841 3/20 0.38
GSK3A P49840 2/20 0.38
DHODH Q02127 1/20 0.38
IGF1R P08069 5/20 0.37
SRC P12931 2/20 0.37
FGFR1 P11362 1/20 0.37
KDR P35968 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
ITK Q08881 1/20 0.37
EIF2AK2 P19525 1/20 0.35
PLK4 O00444 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802687 0.90 PAK4 (0.43) AURKAAURKBGSK3BGSK3ADHODH
SCHEMBL12619888 0.87 DHODH (0.44) AURKAAURKBGSK3BGSK3ADHODH
SCHEMBL802064 0.80 GSK3A (0.42) GSK3BGSK3ACYP1A2ITKSMYD2
SCHEMBL12619885 0.78 DHODH (0.43) AURKAAURKBGSK3BGSK3ADHODH
SCHEMBL801760 0.77 IGF1R (0.47) IGF1R
SCHEMBL801685 0.76 GSK3B (0.47) GSK3BGSK3ACYP1A2CYP3A4CYP2D6
SCHEMBL802074 0.74 CYP1A2 (0.50) AURKAAURKBGSK3BGSK3ASRC
SCHEMBL26669348 0.73 RET (0.45) AURKAAURKBIGF1RFGFR1KDR
SCHEMBL802516 0.72 NPC1 (0.38) IGF1RALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19823081 0.71 RET (0.45) AURKAAURKBIGF1RFGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 AURKA 8/4885AURKB 19/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.